CELCUITY INC. (CELC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$66.12M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$50.51M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$42.85M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$44.01M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$66.12M | (m) | (m) | (m) | $51.00K* | -$55.43M* | (m) | $31.08M | $35.04M | (m) |
| 2026-03-31 | Reported | (m) | -$50.51M | (m) | (m) | (m) | $249.00K | -$55.06M | (m) | $33.06M | $17.44M | (m) |
| 2025-09-30 | Reported | (m) | -$42.85M | (m) | (m) | (m) | $97.00K* | -$44.82M* | (m) | $34.91M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$44.01M | (m) | (m) | (m) | $39.00K* | -$36.21M* | (m) | $36.41M | $7.59M | (m) |
| 2025-03-31 | Reported | (m) | -$36.13M | (m) | (m) | (m) | $60.00K | -$35.85M | (m) | $29.76M | $6.37M | (m) |
| 2024-09-30 | Reported | (m) | -$30.06M | (m) | (m) | (m) | $51.00K* | -$20.56M* | (m) | $27.59M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$24.28M | (m) | (m) | (m) | $64.00K* | -$18.07M* | (m) | $22.50M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$22.49M | (m) | (m) | (m) | $90.00K | -$17.07M | (m) | $20.65M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$18.90M | (m) | (m) | (m) | $53.10K* | -$12.75M* | (m) | $17.49M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$15.06M | (m) | (m) | (m) | $4.85K* | -$9.66M* | (m) | $13.75M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$12.55M | (m) | (m) | (m) | $6.99K | -$12.87M | (m) | $11.28M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$10.64M | (m) | (m) | (m) | $12.10K* | -$9.31M* | (m) | $9.62M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$9.60M | (m) | (m) | (m) | $22.99K* | -$11.29M* | (m) | $8.37M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$7.51M | (m) | (m) | (m) | $11.63K | -$5.93M | (m) | $6.70M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$5.60M | (m) | (m) | (m) | $14.06K* | -$4.05M* | (m) | $4.96M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$13.64M | (m) | (m) | (m) | $26.97K* | -$7.62M* | (m) | $13.07M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$2.79M | (m) | (m) | (m) | $30.93K | -$2.52M | (m) | $2.24M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$2.48M | (m) | (m) | (m) | $8.90K* | -$1.65M* | (m) | $1.96M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$2.21M | (m) | (m) | (m) | $20.98K* | -$1.56M* | (m) | $1.77M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$2.31M | (m) | (m) | (m) | $45.60K | -$1.83M | (m) | $1.85M | (m) | $0.00 |
| 2019-09-30 | Reported | (m) | -$2.09M | (m) | (m) | (m) | $536.32K* | -$1.48M* | (m) | $1.71M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$1.84M | (m) | (m) | (m) | -$231.47K* | -$1.23M* | (m) | $1.47M | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$1.97M | (m) | (m) | (m) | $47.64K | -$1.59M | (m) | $1.59M | (m) | $0.00 |
| 2018-09-30 | Reported | (m) | -$1.98M | (m) | (m) | (m) | $110.14K* | -$1.77M* | (m) | $1.60M | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$1.93M | (m) | (m) | (m) | $168.02K* | -$1.34M* | (m) | $1.55M | (m) | $0.00 |
| 2018-03-31 | Reported | (m) | -$2.08M | (m) | (m) | (m) | $204.26K | -$1.45M | (m) | $1.55M | (m) | $0.00 |
| 2017-09-30 | Reported | (m) | -$1.53M | (m) | (m) | (m) | $37.65K* | -$1.63M* | (m) | $1.36M | (m) | $0.00 |
| 2017-06-30 | Reported | (m) | -$1.61M | (m) | (m) | (m) | $155.47K* | -$1.26M* | (m) | $1.30M | (m) | $0.00 |
| 2017-03-31 | Reported | (m) | -$993.91K | (m) | (m) | (m) | $10.38K | -$947.14K | (m) | $908.77K | (m) | $0.00 |
| 2016-09-30 | Reported | (m) | -$877.54K | (m) | (m) | (m) | (m) | (m) | (m) | $812.80K | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$172.19M | (m) | (m) | (m) | $249.00K | -$153.28M | (m) | $145.00M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$113.27M | (m) | (m) | (m) | $250.00K | -$83.47M | (m) | $104.20M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$66.23M | (m) | (m) | (m) | $97.64K | -$53.81M | (m) | $60.59M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$39.39M | (m) | (m) | (m) | $158.77K | -$36.01M | (m) | $35.29M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$28.36M | (m) | (m) | (m) | $81.90K | -$20.31M | (m) | $25.76M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$9.56M | (m) | (m) | (m) | $89.37K | -$7.15M | (m) | $7.68M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$7.81M | (m) | (m) | (m) | -$380.20K | -$6.00M | (m) | $6.27M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$7.93M | (m) | (m) | (m) | $629.61K | -$6.08M | (m) | $6.33M | (m) | $0.00 |
| 2017-12-31 | Reported | (m) | -$5.95M | (m) | (m) | (m) | $239.85K | -$4.95M | (m) | $4.98M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$3.33M | (m) | (m) | (m) | $40.90K | -$2.89M | (m) | $3.06M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |